North America Diabetic Foot Ulcer Market Forecast to 2030 - Regional Analysis -By Ulcer Type, Treatment Type, Infection Severity, and End User

The North America diabetic foot ulcer market was valued at US$ 3,570.76 million in 2022 and is expected to reach US$ 5,943.56 million by 2030; it is estimated to grow at a CAGR of 6.6% from 2022 to 2030.

Use of 3D Printing in Wound Care Management Fuels the North America Diabetic Foot Ulcer Market.

Skin tissue damage caused by various indications due to diabetes and vascular diseases significantly burdens the healthcare systems. 3D bioprinting is based on layer-based synthesis, wherein the newly generated cells and cell-based materials can be dispensed to mimic native tissues. Though the technology is still nascent, 3D printing can potentially revolutionize the wound care industry. Many companies are involved in developing new products involving ion-release biomaterials that promote angiogenesis for dermal regeneration. In addition, 3D bioprinting helps patch large wounds that are hard to heal with standard techniques. The use of 3D bioprinting technologies in ulcer or wound treatments is likely to emerge as a prominent trend in the diabetic foot ulcer market in the coming years.

North America Diabetic foot ulcer Market Overview

The North America diabetic foot ulcer market is estimated to grow at a CAGR of 6.64% from 2022 to 2030. Key factors driving the market growth are increasing prevalence of diabetes and related chronic wounds and the rise in geriatric population propel market growth. However, high cost of advanced wound care treatments hinders the market growth. The growing geriatric population in the region also boosts the market growth. According to the Administration on Aging (US Department of Health and Human Services) report published in 2022, there were 55.7 million people aged 65 and above in 2020 in the US. The old age group represents 17% of the population, i.e., 1 in every 6 Americans. As per estimates by the Urban Institute (Washington, DC-based think tank), the number of people aged 65 and older will double over the next 40 years, reaching 80 million in 2040 in the US. Additionally, in 2020, diabetes is regarded as among the leading chronic conditions among adults aged 65 and above.

In recent years, several joint ventures, initiatives, and collaborations contributed to accelerating the diabetic foot ulcers market expansion in North America. For instance, in 2020, six research institutions in the US launched the first-ever multicenter network funded by the National Institutes of Health to study diabetic foot ulcers in the US. Additionally, the Diabetic Foot Canada program was launched in Canada to prevent diabetic foot complications. Thus, the high prevalence of diabetes and the increasing geriatric population will drive the market growth in the region.

Nort

h America Diabetic foot ulcer Market Revenue and Forecast to 2030 (US$ Million)

North America Diabetic Foot Ulcer Market Segmentation

Based on treatment type, the North America diabetic foot ulcer market is segmented into advanced wound care dressings, therapy device, and biologics. The advanced wound care dressings segment held largest share in 2022.

Based on ulcer type, the North America diabetic foot ulcer market is segmented into neuro-lschemic ulcers, neuropathic ulcers, and ischemic ulcers. The neuro-lschemic ulcers segment held largest share in 2022.

Based on infection severity, the North America diabetic foot ulcer market is segmented into mild, moderate, and severe. The mild segment held largest share in 2022.

Based on end user, the North America diabetic foot ulcer market is segmented into hospitals, ambulatory surgical centers, and home care. The hospitals segment held largest share in 2022.

Based on country, the North America diabetic foot ulcer market is segmented into US, Canada, and Mexico. The US dominated North America diabetic foot ulcer market in 2022.

Convatec Group Plc, 3M Co, Coloplast AS, Smith & Nephew Plc, B. Braun SE, Medline Industries LP, Organogenesis Inc., Mölnlycke Health Care AB, and MiMedx Group Inc are some of the leading companies operating in the North America diabetic foot ulcer market.

Reasons to Buy

• Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the North America diabetic foot ulcer treatment market.
• Highlights key business priorities in order to assist companies to realign their business strategies
• The key findings and recommendations highlight crucial progressive industry trends in the North America diabetic foot ulcer treatment market, thereby allowing players across the value chain to develop effective long-term strategies
• Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
• Scrutinize in-depth North America market trends and outlook coupled with the factors driving the North America diabetic foot ulcer treatment market, as well as those hindering it
• Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution